The Tf-L-APVN significantly enhanced the synergistic effects of paclitaxel and vorinostat on the proliferation of HepG2 cancer cells and displayed excellent anti-tumor efficacy in HepG2 tumor-bearing mice, making it great potential for HCC therapy. This evidence concerns the gene TF and hepatocellular carcinoma.